Patients with hereditary angioedema using deucrictibant as an on-demand treatment for attacks achieved onset of symptom ...

Pharvaris announced positive results from its ongoing studies of deucrictibant, an oral bradykinin B2 receptor antagonist aimed at treating hereditary angioedema (HAE). In the CHAPTER-1 Open-Label ...

Hereditary angioedema (HAE) attacks are characterized by severe swelling, known as edema, in different parts of the body. These episodes, which generally last from two to five days, may be painful, ...

– Despite currently available treatment options, the majority of surveyed adults with HAE reported making tradeoffs in their daily lives due to the unexpected and unpredictable nature of HAE attacks – ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the presentation of novel sebetralstat data related to laryngeal hereditary ...

Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in CHAPTER-1 ...

Dawnzera (donidalorsen) is a medicine used to prevent attacks of hereditary angioedema (HAE). HAE is a rare genetic condition that is caused by a problem with a gene that makes a blood protein called ...

RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) (Nasdaq: BCRX) today announced new real-world data demonstrating rapid, sustained reduction of ...

Please provide your email address to receive an email when new articles are posted on . Lanadelumab reduced median HAE attack rates by 98.8%. Over 70% of patients increased their dosing interval. The ...

Rapid swelling from hereditary angioedema can result from a variety of triggers. Doctors may use prophylactic medications to try and prevent these episodes, but managing stress and developing healthy ...

Even if you’re doing everything you can to avoid an episode of hereditary angioedema (HAE) — dodging injuries, preventing respiratory illnesses, taking medication — it’s not always possible to ward ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...